Cargando…

Basic Pan-Cancer Analysis of the Carcinogenic Effects of Cyclin-Dependent Kinase 4 (CDK4) in Human Surface Tumors

Although the evidence based on current human, animal, or molecular biology can explain some of the relationships between CDK4 and cancer, there is no pan-cancer analysis of the gene CDK4 in human skin tumors. Therefore, the potential carcinogenic effects of CDK4 in 33 tumors were initially explored...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Jingping, Deng, Tinghan, Huang, Yuanen, Cheng, Hongbin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8371625/ https://www.ncbi.nlm.nih.gov/pubmed/34422248 http://dx.doi.org/10.1155/2021/8493572

Ejemplares similares

An Integrative Human Pan-Cancer Analysis of Cyclin-Dependent Kinase 1 (CDK1)
por: Liu, Xuanyou, et al.
Publicado: (2022)

Comparison of deregulated expression of cyclin D1 and cyclin E with that of cyclin-dependent kinase 4 (CDK4) and CDK2 in human oesophageal squamous cell carcinoma
por: Matsumoto, M, et al.
Publicado: (1999)

Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors: existing and emerging differences
por: Johnston, Stephen, et al.
Publicado: (2023)

A Requirement for Cyclin D3–Cyclin-dependent Kinase (cdk)-4 Assembly in the Cyclic Adenosine Monophosphate–dependent Proliferation of Thyrocytes
por: Depoortere, Fabienne, et al.
Publicado: (1998)

Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers
por: Finn, Richard S., et al.
Publicado: (2016)

Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells
por: Kang, Jian, et al.
Publicado: (2014)

The Cyclin-dependent Kinase Cdk2 Regulates Thymocyte Apoptosis
por: Hakem, Anne, et al.
Publicado: (1999)

Cyclin-dependent kinases and CDK inhibitors in virus-associated cancers
por: Tavakolian, Shaian, et al.
Publicado: (2020)

Cyclin-Dependent Kinases (CDK) and Their Role in Diseases Development–Review
por: Łukasik, Paweł, et al.
Publicado: (2021)

The Role of Cyclin-Dependent Kinases (CDK) 4/6 in the Ovarian Tissue and the Possible Effects of Their Exogenous Inhibition
por: Scavone, Graziana, et al.
Publicado: (2023)

Molecular docking analysis of piperine with CDK2,CDK4,Cyclin D and Cyclin T proteins
por: Rekha, Umapathy Vidhya, et al.
Publicado: (2020)

The HTLV-1 Tax protein binding domain of cyclin-dependent kinase 4 (CDK4) includes the regulatory PSTAIRE helix
por: Fraedrich, Kirsten, et al.
Publicado: (2005)

Predicting clinical benefit from continuation of cyclin dependent kinase (CDK) 4/6 inhibitors beyond progression
por: Foldi, Julia, et al.
Publicado: (2023)

Cyclin-dependent kinase 5 (CDK5) regulates the circadian clock
por: Brenna, Andrea, et al.
Publicado: (2019)

Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer
por: Thill, Marc, et al.
Publicado: (2018)

Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells
por: Ogata, Ryohei, et al.
Publicado: (2020)

Perspective of Cyclin-dependent kinase 9 (CDK9) as a Drug Target
por: Kryštof, Vladimír, et al.
Publicado: (2012)

Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: A multicenter study
por: Yıldırım, Hasan Çağrı, et al.
Publicado: (2022)

Cell cycle progression mechanisms: slower cyclin-D/CDK4 activation and faster cyclin-E/CDK2
por: Zhang, Wengang, et al.
Publicado: (2023)

Concomitant Presence of p16/Cyclin‐dependent Kinase 4 and Cyclin D/Cyclin‐dependent Kinase 4 omplexes in LNCaP Prostatic Cancer Cell Line
por: Itoh, Noriyuki, et al.
Publicado: (1997)

The awakening of the CDK10/Cyclin M protein kinase
por: Guen, Vincent J., et al.
Publicado: (2017)

mTORC1 Down-Regulates Cyclin-Dependent Kinase 8 (CDK8) and Cyclin C (CycC)
por: Feng, Daorong, et al.
Publicado: (2015)

Effects of the Cyclin-Dependent Kinase 10 (CDK10) on the Tamoxifen Sensitivity of Keloid Samples
por: Liu, Ying, et al.
Publicado: (2012)

Lineage specific composition of cyclin D–CDK4/CDK6–p27 complexes reveals distinct functions of CDK4, CDK6 and individual D‐type cyclins in differentiating cells of embryonic origin
por: Bryja, V., et al.
Publicado: (2008)

Phosphorylation of mixed lineage kinase MLK3 by cyclin-dependent kinases CDK1 and CDK2 controls ovarian cancer cell division
por: Cedeno-Rosario, Luis, et al.
Publicado: (2022)

Deciphering the Immunomodulatory Role of Cyclin-Dependent Kinase 4/6 Inhibitors in the Tumor Microenvironment
por: Pandey, Pratibha, et al.
Publicado: (2023)

Cyclin-Dependent Kinase (CDK) Inhibitors: Structure–Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines
por: Coxon, Christopher R., et al.
Publicado: (2016)

Targeting cyclin-dependent kinase 1 (CDK1) in cancer: molecular docking and dynamic simulations of potential CDK1 inhibitors
por: Sofi, Shazia, et al.
Publicado: (2022)

Cyclin-dependent kinase 4/6 inhibition in cancer therapy
por: Johnson, Neil, et al.
Publicado: (2012)

Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells
por: Marko, D, et al.
Publicado: (2001)

The emerging roles and therapeutic potential of cyclin-dependent kinase 11 (CDK11) in human cancer
por: Zhou, Yubing, et al.
Publicado: (2016)

The M-phase specific hyperphosphorylation of Staufen2 involved the cyclin-dependent kinase CDK1
por: Beaujois, Rémy, et al.
Publicado: (2017)

Genome-wide identification of cyclin-dependent kinase (CDK) genes affecting adipocyte differentiation in cattle
por: Pan, Cuili, et al.
Publicado: (2021)

Cyclin-dependent kinase 7 (CDK7) is an emerging prognostic biomarker and therapeutic target in osteosarcoma
por: Ma, Hangzhan, et al.
Publicado: (2021)

Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors
por: Bisi, John E., et al.
Publicado: (2017)

Dinaciclib as an effective pan-cyclin dependent kinase inhibitor in platinum resistant ovarian cancer
por: Howard, David, et al.
Publicado: (2022)

Cytomegalovirus cyclin-dependent kinase ortholog vCDK/pUL97 undergoes regulatory interaction with human cyclin H and CDK7 to codetermine viral replication efficiency
por: Schütz, Martin, et al.
Publicado: (2023)

Clinical CDK4/6 inhibitors induce selective and immediate dissociation of p21 from cyclin D-CDK4 to inhibit CDK2
por: Pack, Lindsey R., et al.
Publicado: (2021)

A cyclin-dependent kinase, CDK11/p58, represses cap-dependent translation during mitosis
por: An, Sihyeon, et al.
Publicado: (2020)

Cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) versus chemotherapy in luminal B early breast cancer: lessons from the CORALLEEN trial
por: De Angelis, Claudia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bhchu2bfggch9psaickbg2ur4h